Long-Term Follow-up, Up to 7 Years, in the RESONATE-2 Study of First-Line Ibrutinib Treatment for Chronic Lymphocytic Leukemia (CLL)-MedSci.cn

Long-Term Follow-up, Up to 7 Years, in the RESONATE-2 Study of First-Line Ibrutinib Treatment for Chronic Lymphocytic Leukemia (CLL)

Burger, J; Barr, P; Owen, C; Robak, T; Tedeschi, A; Bairey, O; Hillmen, P; Coutre, S; Devereux, S; Grosicki, S; McCarthy, H; Li, JY; Offner, F; Moreno, C; Dai, S; Szoke, A; Dean, JP; Kipps, TJ; Ghia, P

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021; 21 (): S316

科室
- - 订阅+
  - 更多科室
工具
服务